DEFA14A: Enhabit Urges Stockholders to Vote for Its Director Nominees Amidst AREX Capital's Takeover Attempt

Enhabit is urging stockholders to vote for its nine director nominees on the YELLOW proxy card, highlighting recent strong operational results and progress in driving value creation amidst a takeover attempt by AREX Capital Management.

Summary

• Enhabit is currently facing an attempt by AREX Capital Management to replace most of its independent directors.
• The company is urging stockholders to vote for Enhabit's nine nominees on the YELLOW proxy card.
• Enhabit highlights three consecutive quarters of strong operational results, including adjusted EBITDA in the range of $24.5 million to $25.0 million.
• The company has reduced debt by $15 million, including a $10 million payment on its revolving credit facility.
• Non-Medicare visits shifting to payor innovation contracts have increased to 43% from 38% in the first quarter of 2024.
• Home Health admissions are up, with Q1 2024 admissions increasing by 5.3% year-over-year and Q2 2024 admissions up 6.4% year-over-year.
• Non-Medicare revenue per visit has increased from $136 per visit in 2022 to $145 in the first quarter of 2024.
• Hospice revenue and admissions are up 2.9% and 6.9%, respectively, from the second quarter of 2022 to the first quarter of 2024.
• Three de novo locations have opened in 2024, in addition to the eight opened in 2023.
• Nursing applications have increased by 30%, and there were 151 net new full-time nursing hires in the first quarter of 2024.
• Institutional Shareholder Services (ISS) has recommended that stockholders vote FOR a majority of Enhabit's director nominees.

Sentiment

Score: 7

Explanation: The document presents a positive outlook on Enhabit's recent performance and strategic initiatives, but the ongoing proxy fight introduces uncertainty.

Positives

• Enhabit has achieved three consecutive quarters of strong operational results.
• The company has reduced debt by $15 million.
• Non-Medicare visits shifting to payor innovation contracts have increased.
• Home Health admissions are up year-over-year.
• Non-Medicare revenue per visit has increased.
• Hospice revenue and admissions are up.
• De novo locations are accelerating top-line growth.
• Nursing applications have increased, and there were 151 net new full-time nursing hires in the first quarter of 2024.
• ISS recommends stockholders vote for a majority of Enhabit's director nominees.

Negatives

• AREX Capital Management is attempting to take control of Enhabit's Board of Directors.

Risks

• The company faces risks related to executing its strategic plans.
• Regulatory and other developments impacting the markets for its services could pose risks.
• Changes in reimbursement rates, general economic conditions, and the mix of payors could affect results.
• The company faces risks related to attracting and retaining key personnel.
• Potential disruptions or breaches of information systems could pose risks.
• The outcome of litigation could pose risks.
• The company faces risks related to successfully completing and integrating de novo locations, acquisitions, investments, and joint ventures.
• The company faces risks related to successfully integrating technology in its operations.
• The company faces risks related to controlling costs, particularly labor and employee benefit costs.
• Impacts resulting from the announcement of the conclusion of the strategic review process could pose risks.

Future Outlook

The company aims to transition its stability into further profitable growth, driven by volume growth in home health, a growing payor network, increasing hospice census and admissions, and de novo strategy advancement.

Management Comments

• The Board and Management are executing the right plan and strategy to drive value creation.
• The company has stabilized the business and achieved significant improvement in performance for three consecutive quarters through the successful execution of key operational initiatives.

Industry Context

The document highlights Enhabit's efforts to navigate challenging industry headwinds and market dynamics in the home health and hospice sector, focusing on payor innovation and operational efficiency.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or comparable companies.
• It focuses on Enhabit's internal progress and achievements since its spin-off from Encompass Health Corporation.

Legal Proceedings

• The company is involved in a lawsuit, Enhabit, Inc. et al. v. Nautic Partners IX, L.P., et al., pending in the Chancery Court of Delaware, asserting claims for breach of fiduciary duty, aiding and abetting, and usurpation of corporate opportunity arising from actions involving its former officers.

Stakeholder Impact

• Stockholders are being asked to make an important decision regarding the composition of the Board of Directors.
• The company's performance impacts employees, patients, and other stakeholders.

Next Steps

• Stockholders are urged to vote using the YELLOW proxy card.
• The company will hold its 2024 annual meeting of stockholders.

Key Dates

Keywords

proxy, directors, stockholders, EBITDA, home health, hospice, Enhabit, AREX